The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: Naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses

Molecular Pharmacology

Volumn 66, Issue 5, 2004, Pages 1180-1191

  Mahata, Sushil K ^a   Mahata, Manjula ^b   Wen, Gen ^b   Wong, William B ^b   Mahapatra, Nitish R ^b   Hamilton, Bruce A ^b   O'Connor, Daniel T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHROMOGRANIN A; GLYCINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PROLINE; PROTEIN SUBUNIT; SERINE; SODIUM 22;

AMINO ACID SEQUENCE; ARTICLE; CATECHOLAMINE RELEASE; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; CHROMAFFIN CELL; COMPETITION; DESENSITIZATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SODIUM TRANSPORT;

AMINO ACID SEQUENCE; ANIMALS; CATECHOLAMINES; CHROMAFFIN CELLS; CHROMOGRANIN A; CHROMOGRANINS; DRUG INTERACTIONS; HUMANS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PC12 CELLS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 6944221313     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.002139     Document Type: Article

References (40)

1. Aardal S, Helle KB, Elsayed S, Reed RK, and Serck-Hanssen G (1993) Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405-412.
2. Anonymous (1995) 1995 Receptor and ion channel nomenclature supplement. Trends Pharmacol Sci Suppl:1-73.
3. Badio B and Daly JW (1994) Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 45:563-569.
4. Bartlett SF and Smith AD (1974) Adrenal chromaffin granules: isolation and disassembly. Methods Enzymol 31:379-389.
5. DeQuattro V and Feng M (2002) The sympathetic nervous system: the muse of primary hypertension. J Hum Hypertens 16 Suppl 1:S64-S69.
6. Falconer DS and Mackay TFC (1996) Introduction to Quantitative Genetics. Addison Wesley Longman, Harlow, UK.
7. Greene LA and Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424-2428.
8. Herrero CJ, Ales E, Pintado AJ, Lopez MG, Garcia-Palomero E, Mahata SK, O'Connor DT, Garcia AG, and Montiel C (2002) Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis. J Neurosci 22:377-388.
9. Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, et al. (2003) Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry 42:6938-6946.
10. Li YF, Gong ZH, Cao JB, Wang HL, Luo ZP, and Li J (2003) Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 469:81-88.
11. Lopez MG, Montiel C, Herrero CJ, Garcia-Palomero E, Mayorgas I, Hernandez-Guijo JM, Villarroya M, Olivares R, Gandia L, McIntosh JM, et al. (1998) Unmasking the functions of the chromaffin cell alpha7 nicotinic receptor by using short pulses of acetylcholine and selective blockers. Proc Natl Acad Sci USA 95:14184-14189.
12. Mahapatra NR, Mahata M, O'Connor DT, and Mahata SK (2003) Secretin activation of chromogranin A gene transcription. Identification of the signaling pathways in cis and in trans. J Biol Chem 278:19986-19994.
13. Mahata M, Mahapatra NR, O'Connor DT, and Mahata SK (2002) Chromaffin cell catecholamine secretion: bisindolylmaleimide compounds exhibit novel and potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. Mol Pharmacol 61:1340-1347.
14. Mahata M, Mahata SK, Parmer RJ, and O'Connor DT (1996) Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. Hypertension 28:414-420.
15. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, and O'Connor DT (2003) Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058-32067.
16. Mahata SK, Mahata M, Parmer RJ, and O'Connor DT (1999) Desensitization of catecholamine release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 274:2920-2928.
17. Mahata SK, Mahata M, Wakade AR, and O'Connor DT (2000) Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525-1535.
18. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, and Parmer RJ (1997) Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a non competitive nicotinic cholinergic antagonist. J Clin Investig 100:1623-1633.
19. McLane KE, Wu XD, and Conti-Tronconi BM (1990) Identification of a brain acetylcholine receptor α subunit able to bind α-bungarotoxin. J Biol Chem 265:9816-9824.
20. O'Connor DT, Frigon RP, and Sokoloff RL (1984) Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. Hypertension 6:2-12.
21. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, and Parmer RJ (2002) Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335-1345.
22. O'Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK, Wu H, Kennedy BP, Ziegler MG, et al. (1999) Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 8:285-295.
23. Preece NE, Nguyen M, Mahata M, Mahata SK, Mahapatra NR, Tsigelny I, and O'Connor DT (2004) Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regul Pept 118:75-87.
24. Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, and Esler MD (2000) The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens 18: 717-723.
25. Schober M, Howe PR, Sperk G, Fischer-Colbrie R, and Winkler H (1989) An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats. Hypertension 13:469-474.
26. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Parmer RJ, Barbosa JA, and O'Connor DT (1990) Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81:185-195.
27. Takiyyuddin MA, De Nicola L, Gabbai FB, Dinh TQ, Kennedy B, Ziegler MG, Sabban EL, Parmer RJ, and O'Connor DT (1993) Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension 21: 674-679.
28. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, et al. (1995) Chromogranin A in human hypertension. Influence of heredity. Hypertension 26:213-220.
29. Tang K, Wu H, Mahata SK, Mahata M, Gill BM, Parmer RJ, and O'Connor DT (1997) Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C. J Clin Investig 100:1180-1192.
30. Tang K, Wu H, Mahata SK, and O'Connor DT (1998) A crucial role for the mitogen-activated protein kinase pathway in nicotinic cholinergic signaling to secretory protein transcription in pheochromocytoma cells. Mol Pharmacol 54:59-69.
31. Tang K, Wu H, Mahata SK, Taupenot L, Rozansky DJ, Parmer RJ, and O'Connor DT (1996) Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin A biosynthesis. J Biol Chem 271:28382-28390.
32. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, and Barchas JD (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature (Lond) 324:476-478.
33. Taupenot L, Mahata M, Mahata SK, and O'Connor DT (1999) Time-dependent effects of the neuropeptide PACAP on catecholamine secretion. Stimulation and desensitization. Hypertension 34:1152-1162.
34. Taupenot L, Mahata SK, Wu H, and O'Connor DT (1998) Peptidergic activation of transcription and secretion in chromaffin cells, cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). J Clin Investig 101:863-876.
35. Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothornsrikul S, Toneff T, Caporale C, Jiang Q, Parmer RJ, et al. (2000) Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem 275:22905-22915.
36. Tischler AS, Powers JF, and Alroy J (2004) Animal models of pheochromocytoma. Histol Histopathol 19:883-895.
37. Tsigelny I, Mahata SK, Taupenot L, Preece NE, Mahata M, Khan I, Parmer RJ and O'Connor DT (1998) Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a b-strand/loop/b-strand structure secured by hydrophobic interactions and predictive of activity. Regul Pept 77:43-53.
38. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O'Connor DT and Hamilton BA (2004) Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 74:197-207.
39. Winkler H and Fischer-Colbrie R (1992) The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49:497-528.
40. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, and O'Connor DT (1991) Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. J Biol Chem 266:13130-13134.